Q32 Bio Inc.
A clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
QTTB | US
Overview
Corporate Details
- ISIN(s):
- US7469641051 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 830 WINTER STREET, 2451 WALTHAM
- Website:
- https://www.q32bio.com/
Description
Q32 Bio Inc. is a clinical-stage biotechnology company developing therapies to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company's therapeutic approach targets powerful regulators of both the innate and adaptive immune systems. Its most advanced product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody. Bempikibart is designed to re-regulate adaptive immune function by blocking signaling from both interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP). The candidate is currently being evaluated in a Phase 2 program for the treatment of alopecia areata.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Q32 Bio Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Q32 Bio Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Q32 Bio Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
